Idebenone treatment in patients with OPA1-mutant dominant optic atrophy

Brain

Volumn 136, Issue 2, 2013, Pages

  Barboni, Piero ^a,b   Valentino, Maria Lucia ^b,c   La Morgia, Chiara ^b,c   Carbonelli, Michele ^a   Savini, Giacomo ^d   De Negri, Annamaria ^e   Simonelli, Francesca ^f   Sadun, Federico ^g   Caporali, Leonardo ^b,c   Maresca, Alessandra ^b,c   Liguori, Rocco ^b,c   Baruzzi, Agostino ^b,c   Zeviani, Massimo ^h   Carelli, Valerio ^b,c  

^a Studio Oculistico d'Azeglio   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c IRCCS   (Italy)

^d IRCCS FONDAZIONE BIETTI   (Italy)

^e SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g Ospedale San Giovanni Evangelista   (Italy)

^h DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IDEBENONE; MITOCHONDRIAL DNA; OPA1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; AUTOSOMAL DOMINANT OPTIC ATROPHY; CLINICAL ARTICLE; COLOR DISCRIMINATION; FEMALE; GENE MUTATION; HAPLOINSUFFICIENCY; HUMAN; KOLMOGOROV SMIRNOV TEST; LETTER; MALE; MEMBRANE; NERVE CELL DEGENERATION; OPEN STUDY; OPTIC DISK; OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE PHOSPHORYLATION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA GANGLION CELL; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 84874316439     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws280     Document Type: Letter

References (20)

1. Alexander C, Votruba M, Pesch UEA, Thiselton DL, Mayer S, Moore A, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to choromosome 3q28. Nat Genet 2000; 26: 211-15.
2. Barboni P, Carbonelli M, Savini G, Foscarini B, Parisi V, Valentino ML, et al. OPA1 mutations associated with dominant optic atrophy influence optic nerve head size. Ophthalmology 2010; 117: 1547-53.
3. Carelli V, La Morgia C, Valentino ML, Barboni P, Ross-Cisneros FN, Sadun AA. Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders. Biochim Biophys Acta 2009; 1787: 518-28.
4. Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, et al. Idebenone treatment in Leber's hereditary optic neuropathy. Brain 2011; 134: e188.
5. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Ret Eye Res 2004; 23: 58-89.
6. Cohn AC, Toomes C, Hewitt AW, Kearns LS, Inglehearn CF, Craig JE, et al. The natural history of OPA1-related autosomal dominant optic atrophy. Br J Ophthalmol 2008; 92: 1333-6.
7. Cornille K, Milea D, Amati-Bonneau P, Procaccio V, Zazoun L, Guillet V, et al. Reversible optic neuropathy with OPA1 exon 5b mutation. Ann Neurol 2008; 63: 667-71.
8. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 2000; 26: 207-10.
9. Geromel V, Darin N, Chretien D, Benit P, DeLonlay P, Rotig A, et al. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol Genet Metab 2002; 77: 21-30.
10. Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. PLoS One 2011; 6: e17963.
11. Kjer P. Infantile optic atrophy with dominant mode of inheritance: a clinical and genetic study of 19 Danish families. Acta Ophthalmol Scand 1959; 37: 1-146.
12. Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011; 134: 2677-86.
13. Landes T, Leroy I, Bertholet A, Diot A, Khosrobakhsh F, Daloyau M, et al. OPA1 (dys)functions. Semin Cell Dev Biol 2010; 21: 593-8.
14. Savini G, Barboni P, Parisi V, Carbonelli M. The influence of axial length on retinal nerve fiber layer thickness and optic disc size measurements by spectral-domain OCT. Br J Ophthalmol 2012; 96: 57-61.
15. Savini G, Carbonelli M, Barboni P. Retinal nerve fiber layer thickness measurement by Fourier-domain optical coherence tomography: a comparison between Cirrus HD-OCT and RTVue in healthy eyes. J Glaucoma 2010; 19: 369-72.
16. Votruba M, Moore AT, Bhattacharya SS. Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy. J Med Genet 1998; 35: 793-800.
17. Yarosh W, Monserrate J, Tong JJ, Tse S, Le PK, Nguyen K, et al. The molecular mechanisms of OPA1-mediated optic atrophy in Drosophila model and prospects for antioxidant treatment. PLoS Genet 2008; 4: e6.
18. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies-disease mechanisms and therapeutic strategies. Prog Retin Eye Res 2011; 30: 81-114.
19. Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010; 133: 771-86.
20. Zanna C, Ghelli A, Porcelli AM, Karbowski M, Youle RJ, Schimpf S, et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 2008; 131: 352-67.